Literature DB >> 7912234

Intratumoral heterogeneity for amplified genes in human breast carcinoma.

U Lönn1, S Lönn, B Nilsson, B Stenkvist.   

Abstract

Intratumoral heterogeneity was studied in human breast cancer by examining separate tumor lesions of individual patients. Tumor samples were obtained from each patient by fine-needle biopsies from 2 to 4 separate tumor lesions. We used a semi-quantitative PCR to distinguish between samples with gene amplification and single gene copy samples. Five genes were analyzed in each biopsy: MDR-1, dihydrofolate reductase, thymidylate synthase, c-erb-B2 and int-2. Three groups of patients were examined: those awaiting initiation of treatment; those receiving first-line endocrine therapy; and those receiving second-line endocrine treatment. A pattern of intratumoral heterogeneity for gene amplification was clearly apparent. The frequency of amplification was lowest before initiating therapy and highest in patients receiving second-line treatment (p = 0.023).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912234     DOI: 10.1002/ijc.2910580108

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Fast isolation of RNA to detect expression of tumor markers.

Authors:  J A Schenk; T Hillebrand; L Lübbe; S Heymann; M Böttger; B Micheel; P Bendzko
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  4-Hydroxytamoxifen differentially exerts estrogenic and antiestrogenic effects on discrete subpopulations of human breast cancer cells.

Authors:  S T Willard; E J Abrahman; W J Faught; D C Leaumont; L S Frawley
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

3.  The establishment of sublines with opposite chemosensitivity from a patient with pulmonary large cell carcinoma and the implementation of treatment based on tumor heterogeneity.

Authors:  S Kobayashi; S Okada; T Hasumi; N Sato; S Fujimura
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.

Authors:  S Withoff; W N Keith; A J Knol; J C Coutts; S F Hoare; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance.

Authors:  Shuang Liu; Young-Seung Kim; Shizhen Zhai; Jiyun Shi; Guihua Hou
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

Review 6.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

7.  Expression of a truncated form of hHb1 hair keratin in human breast carcinomas.

Authors:  C H Régnier; A Boulay; P H Asch; C Wendling; M P Chenard; C Tomasetto; M C Rio
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

8.  Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.

Authors:  Shengwen Calvin Li; Lisa May Ling Tachiki; Mustafa H Kabeer; Brent A Dethlefs; Michael J Anthony; William G Loudon
Journal:  Cancer Cell Int       Date:  2014-11-12       Impact factor: 5.722

9.  Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.

Authors:  Katharina Malinowsky; Mithu Raychaudhuri; Theresa Buchner; Sabrina Thulke; Claudia Wolff; Heinz Höfler; Karl-Friedrich Becker; Stefanie Avril
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.